Properties (66)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
AbbVie
|
| gptkbp:businessModel |
strategic partnerships
biotechnology innovation achieve market entry for vaccines |
| gptkbp:clinicalTrials |
ongoing studies
published in medical journals multiple phases of development Phase 1 and Phase 2 trials aim for improved patient health conducted for vaccine candidates recruited from diverse populations various_sites_across_the_U.S. |
| gptkbp:collaborations |
with government agencies
|
| gptkbp:communityEngagement |
participation in health initiatives
|
| gptkbp:communityPartnerships |
with healthcare providers
with local health organizations |
| gptkbp:corporateSocialResponsibility |
commitment to public health
|
| gptkbp:employeeCount |
approximately 50
|
| gptkbp:financialPerformance |
participation in industry events
protected innovations |
| gptkbp:focus |
vaccine development
|
| gptkbp:founded |
2005
|
| gptkbp:founder |
gptkb:Dr._John_D._McKinney
|
| gptkbp:funding |
government and private grants
|
| gptkbp:hasArea |
conducted for safety and efficacy
|
| gptkbp:hasPrograms |
composed of industry experts
|
| gptkbp:hasResearchInterest |
conducted for vaccine needs
|
| gptkbp:headquarters |
gptkb:Bozeman,_Montana
|
| gptkbp:historicalResearch |
with pharmaceutical companies
focused on vaccine efficacy |
| https://www.w3.org/2000/01/rdf-schema#label |
LigoCyte Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:investmentFocus |
venture capital
venture capital firms |
| gptkbp:keyPeople |
gptkb:Dr._John_D._McKinney
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
gptkb:North_America
planned for future vaccines strategies for new vaccines |
| gptkbp:marketSegment |
focus on unmet medical needs
|
| gptkbp:notable_player |
aimed at public health improvement
|
| gptkbp:notableEvent |
gptkb:LigoCyte's_influenza_vaccine
|
| gptkbp:partnerships |
various academic institutions
with research institutions |
| gptkbp:patentCitation |
held for vaccine technologies
|
| gptkbp:productLine |
diverse vaccine candidates
|
| gptkbp:products |
biologics
in progress for multiple vaccines |
| gptkbp:regulatoryCompliance |
FDA_approval_for_products
adherence_to_FDA_guidelines |
| gptkbp:research |
diverse funding avenues.
grants and private investments |
| gptkbp:researchAreas |
infectious diseases
|
| gptkbp:researchFocus |
novel vaccine technologies
|
| gptkbp:researchInterest |
with universities
published research articles awarded for vaccine studies |
| gptkbp:scientificName |
eminent researchers in the field
|
| gptkbp:strategicGoals |
expand vaccine portfolio
|
| gptkbp:sustainabilityPractices |
environmentally responsible operations
|
| gptkbp:takesPlaceIn |
in development for various diseases
|
| gptkbp:technology |
to commercial partners
virus-like particle technology |
| gptkbp:type |
private company
|
| gptkbp:website |
www.ligocyte.com
|